Metabolic Reprogramming of Macrophages in Atherosclerosis: Is It All about Cholesterol?

키워드

참고문헌 (93)

1. Anitschkow N, "Classics in arteriosclerosis research: on experimental cholesterin steatosis and its significance in the origin of some pathological processes", Arteriosclerosis, 3, pp.178~182 (1983)
2. Han CZ, "Metabolic connections during apoptotic cell engulfment", Cell, 147, pp.1442~1445 (2011)
3. Tabas I, "Macrophage death and defective inflammation resolution in atherosclerosis", Nat Rev Immunol, 10, pp.36~46 (2010)
4. Koelwyn GJ, "Regulation of macrophage immunometabolism in atherosclerosis", Nat Immunol, 19, pp.526~537 (2018)
5. Spann NJ, "Sterols and oxysterols in immune cell function", Nat Immunol, 14, pp.893~900 (2013)
6. Tall AR, "Cholesterol, inflammation and innate immunity", Nat Rev Immunol, 15, pp.104~116 (2015)
7. Yvan-Charvet L, "Immunometabolic function of cholesterol in cardiovascular disease and beyond", Cardiovasc Res, 115, pp.1393~1407 (2019)
8. Giugliano RP, "Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab : a prespecified secondary analysis of the FOURIER trial", Lancet, 390, pp.1962~1971 (2017)
9. Ridker PM, "Residual inflammatory risk : addressing the obverse side of the atherosclerosis prevention coin", Eur Heart J, 37, pp.1720~1722 (2016)
10. Benjamin EJ, "Heart disease and stroke statistics-2017 update : a report from the American Heart Association", Circulation, 135, pp.e146~e603 (2017)
11. Christ A, "Western diet and the immune system : an inflammatory connection", Immunity, 51, pp.794~811 (2019)
12. Linton MF, "Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation", Science, 267, pp.1034~1037 (1995)
13. Yvan-Charvet L, "Poststatin era in atherosclerosis management : lessons from epidemiologic and genetic studies", Curr Opin Lipidol, 29, pp.246~258 (2018)
14. Kim K, "Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models", Circ Res, 123, pp.1127~1142 (2018)
15. Fernandez DM, "Single-cell immune landscape of human atherosclerotic plaques", Nat Med, 25, pp.1576~1588 (2019)
16. Binder CJ, "Innate sensing of oxidation-specific epitopes in health and disease", Nat Rev Immunol, 16, pp.485~497 (2016)
17. Grebe A, "NLRP3 inflammasome and the IL-1 pathway in atherosclerosis", Circ Res, 122, pp.1722~1740 (2018)
18. Murphy AJ, "IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome", Cell Metab, 23, pp.155~164 (2016)
19. Jordan S, "Dietary intake regulates the circulating inflammatory monocyte pool", Cell, 178, pp.1102~1114 (2019)
20. Flaherty SE 3rd, "A lipase-independent pathway of lipid release and immune modulation by adipocytes", Science, 363, pp.989~993 (2019)
21. Brown RJ, "Lipases as modulators of atherosclerosis in murine models", Curr Drug Targets, 8, pp.1307~1319 (2007)
22. Babaev VR, "Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice", J Biol Chem, 275, pp.26293~26299 (2000)
23. Takahashi M, "Macrophage lipoprotein lipase modulates the development of atherosclerosis but not adiposity", J Lipid Res, 54, pp.1124~1134 (2013)
24. Chang CL, "Lipoprotein lipase deficiency impairs bone marrow myelopoiesis and reduces circulating monocyte levels", Arterioscler Thromb Vasc Biol, 38, pp.509~519 (2018)
25. Chang HR, "Role of LpL(lipoprotein lipase)in macrophage polarization in vitro and in vivo", Arterioscler Thromb Vasc Biol, 39, pp.1967~1985 (2019)
26. Haemmerle G, "Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase", Science, 312, pp.734~737 (2006)
27. Schoiswohl G, "Impact of reduced ATGL-mediated adipocyte lipolysis on obesity-associated insulin resistance and inflammation in male mice", Endocrinology, 156, pp.3610~3624 (2015)
28. Kosteli A, "Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue", J Clin Invest, 120, pp.3466~3479 (2010)
29. Lumeng CN, "Inflammatory links between obesity and metabolic disease", J Clin Invest, 121, pp.2111~2117 (2011)
30. Osborn O, "The cellular and signaling networks linking the immune system and metabolism in disease", Nat Med, 18, pp.363~374 (2012)
31. Ely BR, "Meeta-inflammation and cardiometabolic disease in obesity: can heat therapy help?", Temperature (Austin), 5, pp.9~21 (2017)
32. Cooke AA, "Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome", Eur J Pharmacol, 785, pp.207~214 (2016)
33. Perry RJ, "Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes", Cell, 160, pp.745~758 (2015)
34. Schweiger M, "Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice", Nat Commun, 8, pp.14859~ (2017)
35. Lass A, "Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome", Cell Metab, 3, pp.309~319 (2006)
36. Yang X, "The G0", G1 switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase, 2010, pp.11, 194~205
37. Zhang X, "Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia", eLife, 6, pp.e31132~ (2017)
38. Padmanabha Das KM, "Hypoxia-inducible lipid droplet-associated protein inhibits adipose triglyceride lipase", J Lipid Res, 59, pp.531~541 (2018)
39. Heckmann BL, "Defective adipose lipolysis and altered global energy metabolism in mice with adipose overexpression of the lipolytic inhibitor G0", G1 switch gene 2(G0S2), 2014, pp.289, 1905~1916
40. Shin H, "Lipolysis in brown adipocytes is not essential for cold-induced thermogenesis in mice", Cell Metab, 26, pp.764~777 (2017)
41. van Dierendonck XA, "HILPDA uncouples lipid storage in adipose tissue macrophages from inflammation and metabolic dysregulation", bioRxiv, 566802~ (2019)
42. Febbraio M, "Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis", Arterioscler Thromb Vasc Biol, 24, pp.2333~2338 (2004)
43. Zhao L, "Lack of myeloid Fatp1 increases atherosclerotic lesion size in Ldlr-", -mice, 2017, pp.266, 182~189
44. Huang SC, "Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages", Nat Immunol, 15, pp.846~855 (2014)
45. Samovski D, "Regulation of AMPK activation by CD36 links fatty acid uptake to β-oxidation", Diabetes, 64, pp.353~359 (2015)
46. Chen Y, "Mitochondrial metabolic reprogramming by CD36 signaling drives macrophage inflammatory responses", Circ Res, 125, pp.1087~1102 (2019)
47. Johnson AR, "Metabolic reprogramming through fatty acid transport protein 1(FATP1)regulates macrophage inflammatory potential and adipose inflammation", Mol Metab, 5, pp.506~526 (2016)
48. Makowski L, "Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis", Nat Med, 7, pp.699~705 (2001)
49. Makowski L, "The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities", J Biol Chem, 280, pp.12888~12895 (2005)
50. Boord JB, "Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia", Arterioscler Thromb Vasc Biol, 22, pp.1686~1691 (2002)
51. Ménégaut L, "Macrophage fatty acid metabolism and atherosclerosis : the rise of PUFAs", Atherosclerosis, 291, pp.52~61 (2019)
52. Chandak PG, "Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase", J Biol Chem, 285, pp.20192~20201 (2010)
53. Aflaki E, "Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis", Cell Mol Life Sci, 68, pp.3933~3947 (2011)
54. Lammers B, "Macrophage adipose triglyceride lipase deficiency attenuates atherosclerotic lesion development in low-density lipoprotein receptor knockout mice", Arterioscler Thromb Vasc Biol, 31, pp.67~73 (2011)
55. Goeritzer M, "Active autophagy but not lipophagy in macrophages with defective lipolysis", Biochim Biophys Acta, 1851, pp.1304~1316 (2015)
56. Sekiya M, "Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis", Cell Metab, 10, pp.219~228 (2009)
57. Ghosh S, "Important considerations for evaluating the data presented by Igarashi et al", Circ Res, 108, pp.e6~e7 (2011)
58. Kratky D, "Neutral cholesterol ester hydrolases in macrophages : still a matter of debate", Circ Res, 108, pp.e13~ (2011)
59. Emanuel R, "Induction of lysosomal biogenesis in atherosclerotic macrophages can rescue lipid-induced lysosomal dysfunction and downstream sequelae", Arterioscler Thromb Vasc Biol, 34, pp.1942~1952 (2014)
60. Sergin I, "Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis", Nat Commun, 8, pp.15750~ (2017)
61. Zhang X, "Classical and alternative roles for autophagy in lipid metabolism", Curr Opin Lipidol, 29, pp.203~211 (2018)
62. Zhang H, "CRISPR", Cas9-mediated gene editing in human iPSC-derived macrophage reveals lysosomal acid lipase function in human macrophages-brief report, 2017, pp.37, 2156~2160
63. Razani B, "Autophagy links inflammasomes to atherosclerotic progression", Cell Metab, 15, pp.534~544 (2012)
64. Viaud M, "Lysosomal cholesterol hydrolysis couples efferocytosis to anti-inflammatory oxysterol production", Circ Res, 122, pp.1369~1384 (2018)
65. Schlager S, "Lysosomal lipid hydrolysis provides substrates for lipid mediator synthesis in murine macrophages", Oncotarget, 8, pp.40037~40051 (2017)
66. Du H, "Lysosomal acid lipase and atherosclerosis", Curr Opin Lipidol, 15, pp.539~544 (2004)
67. Yan C, "Macrophage-specific expression of human lysosomal acid lipase corrects inflammation and pathogenic phenotypes in lal-", -mice, 2006, pp.169, 916~926
68. Serhan CN, "Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology", Mol Aspects Med, 58, pp.1~11 (2017)
69. Kasikara C, "The role of non-resolving inflammation in atherosclerosis", J Clin Invest, 128, pp.2713~2723 (2018)
70. Bäck M, "Inflammation and its resolution in atherosclerosis : mediators and therapeutic opportunities", Nat Rev Cardiol, 16, pp.389~406 (2019)
71. Serhan CN, "The resolution code of acute inflammation : Novel pro-resolving lipid mediators in resolution", Semin Immunol, 27, pp.200~215 (2015)
72. Fredman G, "An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques", Nat Commun, 7, pp.12859~ (2016)
73. Viola JR, "Resolving lipid mediators Maresin 1 and Resolvin D2 prevent atheroprogression in mice", Circ Res, 119, pp.1030~1038 (2016)
74. Kanter JE, "Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1", Proc Natl Acad Sci U S A, 109, pp.E715~E724 (2012)
75. Schneider JG, "Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis", J Biol Chem, 285, pp.23398~23409 (2010)
76. Powell DR, "Fatty acid desaturase 1 knockout mice are lean with improved glycemic control and decreased development of atheromatous plaque", Diabetes Metab Syndr Obes, 9, pp.185~199 (2016)
77. Saito R, "Macrophage Elovl6 deficiency ameliorates foam cell formation and reduces atherosclerosis in low-density lipoprotein receptor-deficient mice", Arterioscler Thromb Vasc Biol, 31, pp.1973~1979 (2011)
78. Rogers IS, "Imaging of coronary inflammation with FDG-PET : feasibility and clinical hurdles", Curr Cardiol Rep, 13, pp.138~144 (2011)
79. Hag AM, "18F-FDG PET imaging of murine atherosclerosis : association with gene expression of key molecular markers", PLoS One, 7, pp.e50908~ (2012)
80. Lee SJ, "Oxidized low-density lipoprotein stimulates macrophage 18F-FDG uptake via hypoxia-inducible factor-1α activation through Nox2-dependent reactive oxygen species generation", J Nucl Med, 55, pp.1699~1705 (2014)
81. Garcia-Garcia HM, "Imaging plaques to predict and better manage patients with acute coronary events", Circ Res, 114, pp.1904~1917 (2014)
82. Kim EJ, "Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-fluorodeoxyglucose positron emission tomograpic imaging", Circ Cardiovasc Imaging, 7, pp.454~460 (2014)
83. Emami H, "Splenic metabolic activity predicts risk of future cardiovascular events : demonstration of a cardiosplenic axis in humans", JACC Cardiovasc Imaging, 8, pp.121~130 (2015)
84. van der Valk FM, "Increased haematopoietic activity in patients with atherosclerosis", Eur Heart J, 38, pp.425~432 (2017)
85. Robbins CS, "Extramedullary hematopoiesis generates Ly-6Chigh monocytes that infiltrate atherosclerotic lesions", Circulation, 125, pp.364~374 (2012)
86. Roussel R, "Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes : a perspective on glucose-lowering interventions", Diabetes Obes Metab, 20, pp.238~244 (2018)
87. Ross S, "Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease", Eur Heart J, 36, pp.1454~1462 (2015)
88. Ahmad OS, "A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease", Nat Commun, 6, pp.7060~ (2015)
89. Sarrazy V, "Disruption of Glut1 in hematopoietic stem cells prevents myelopoiesis and enhanced glucose flux in atheromatous plaques of ApoE-", -mice, 2016, pp.118, 1062~1077
90. Morioka S, "Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release", Nature, 563, pp.714~718 (2018)
91. Freemerman AJ, "Myeloid Slc2a1-deficient murine model revealed macrophage activation and metabolic phenotype are fueled by GLUT1", J Immunol, 202, pp.1265~1286 (2019)
92. Haschemi A, "The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism", Cell Metab, 15, pp.813~826 (2012)
93. Sarrazy V, "Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation", Cell Reports, 13, pp.132~144 (2015)

관련 논문AI추천